PALOMA-3: Key Safety Data

Opinion
Video

Panelists discuss how treatment-emergent adverse events were comparable among patients treated with subcutaneous amivantamab-lazertinib vs intravenous administration in the PALOMA-3 trial.

Recent Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content